Migraine prevention guidelines elevate CGRP drugs after a 14-year gap
After 14 years without a revision, US neurologists and headache specialists have folded CGRP-targeted drugs into the front rank of migraine prevention. That changes the first conversation in the clinic and the coverage fight behind it.
The Scientist · Science desk
What happened
- The American Academy of Neurology and the American Headache Society published their first migraine prevention update since 2012 on August 31 in the journal Neurology.
- Five CGRP-targeting drugs, atogepant, eptinezumab, erenumab, fremanezumab and galcanezumab, received high marks for both efficacy and tolerability in the review behind the recommendations.
- For the first time the guidance sets a numeric threshold for offering prevention: at least four migraine or severe headache days a month, or migraine that interferes with work or daily tasks.
- Older treatments remain in the document, including propranolol for episodic migraine, topiramate and Botox for chronic migraine, credited with more long-term safety data.
- The CGRP drugs are also recommended for patients who lean heavily on acute pain medication once an attack has started.
Why it matters
- Who has to decide decision With the American Headache Society already calling CGRP-targeted prevention first-line, the burden in an appointment moves toward explaining why an eligible patient is not on one of these drugs.
- Who's exposed exposure Kempner, the Rutgers sociologist who studies pain politics, says a strong recommendation gives physicians ammunition in prior-authorization fights, putting payer denial rationales in play, though she adds that outcomes still hinge on patients affording care.
- What it limits constraint Charles, who runs UCLA's migraine program, expects the sorting by patient category to deter primary care doctors, which would confine the guideline's practical reach to specialist practices.
- What it costs cost Because beta-blockers and antiseizure drugs stay in the guideline for patients wanting lower cost or a longer track record, the cheaper prescription remains defensible and the cost argument stays open rather than being closed by the update.
Next story · Leadership · yesterday
HHS sends the White House a peptide access policy for specialty pharmaciesConfirmed2 publishers
Coverage of this update leans on one number: "up to 70 percent," which Science News gives as the share of people who get fewer migraines on CGRP-targeted drugs such as Aimovig and Ajovy [24]. That figure is a ceiling, not an average, and the source does not say how large a reduction counts or over what period. It also does not say which patients land at the top of that range.
The guideline leaves that unspecified too. CGRP levels rise during a migraine attack and fall once the attack has been treated or has resolved, which is what makes these drugs mechanism-based rather than repurposed from cardiology or epilepsy [17]. But the common form of migraine is not driven by a single mutation, Mayo Clinic neurologist Amaal Starling told Science News; it involves multiple genetic variants that build vulnerability [16]. No assay sorts responders from non-responders in advance, so selection still runs on delivery preference and comorbidity, with Starling's rule of thumb being the medication a patient will actually take [19]. The options include tablets, injections under the skin, and infusions into a vein [20]. STAT reports the recommendations are organised by which property you are prioritising, with separate tracks for patients who have a high body mass index, fibromyalgia or hypertension, or who might be pregnant [14].
That makes the reassessment window the operative clock. Three sequential attempts at eight to twelve weeks each occupy 24 to 36 weeks, roughly six to nine months of a patient's year, before anyone knows whether the third choice works [23]. For a sense of why the revision was overdue: at least six preventives won FDA approval after 2012 [3], which across the 14-year gap between guidelines is about one every 28 months [22].
The two population figures in these accounts are not the same denominator. Science News puts the group the guideline says should be offered prevention at roughly 8 million US adults [25]; STAT reports an estimated 15 percent of Americans experience migraine, with women disproportionately affected [10]. Neither publisher reconciles them, and the smaller figure is the one attached to the new eligibility language, where the older guidance had no explicit criteria at all [5]. Guideline co-author Rebecca Burch said population studies show many more patients with migraine are eligible than are being treated [8].
One conflict the guideline will not settle: its scientific review found the tricyclic amitriptyline a viable option for some pregnant patients, while the American College of Obstetricians and Gynecologists advises against tricyclics in pregnancy over the risk of major congenital abnormalities and other serious problems, according to STAT [15]. The guideline and ACOG disagree, and nothing in either document tells a clinician how to choose between them.
Migraine prevention now has drugs aimed at the disease, but the field still lacks a test aimed at the patient. What the update buys is clarity about whom to treat; the sequencing remains trial and error on an eight-to-twelve-week cycle.
What to watch
- Whether payers rewrite prior-authorization criteria to cite the AAN and AHS recommendation, which is the test of Kempner's ammunition claim.
- Whether the guideline authors or ACOG resolve the amitriptyline-in-pregnancy disagreement rather than leaving clinicians to pick a society.
- Any published data on uptake among primary care prescribers, or a simplified version of the recommendations aimed at them.
Clarity's read
What the record supports and how the coverage leans. The claims behind it follow.
Reality
- Evidence63
- Adoption46
- Hype gap+14
- Incentives60
- Confidence66
Claim ledger
Ranked by verification strength, evidence, and original report placement.
- [1]
For the first time in 14 years, the American Academy of Neurology and the American Headache Society updated their guidelines for preventing migraine attacks, published August 31 in Neurology.
- [2]
The guidance from the American Headache Society and the American Academy of Neurology was released Monday; the two groups last updated their recommendations in 2012.
- [3]
Among the key updates are at least a half dozen medications approved for migraine prevention by the FDA since 2012, many of them focused on blocking the CGRP pathway.
- [4]
The new guidelines advise doctors to offer preventive treatment to people who have at least four migraine or severe headache days per month, or whose migraines interfere with their ability to work or complete daily tasks.
- [5]
The previous guidelines did not include explicit criteria for which patients are eligible for preventive treatment.
- [6]
Beta-blockers such as propranolol and metoprolol and certain antiseizure medications, recommended by the previous guidelines, appear in the updated guidelines as options for patients who want a medication with a longer track record or a lower cost than CGRP-targeted drugs.
- [7]
The guidelines also highlight older treatments with more long-term safety data, including Botox for chronic migraine, propranolol for episodic migraine, and the anti-seizure drug topiramate.
- [8]
Rebecca Burch, guideline co-author and neurologist at the University of Vermont Medical Center, said studies of the U.S. population show many more patients with migraine are eligible for preventive treatment.
- [9]
Newer CGRP-targeting medications atogepant (Qulipta), eptinezumab (Vyepti), erenumab (Aimovig), fremanezumab (Ajovy) and galcanezumab (Emgality) received high marks for their efficacy and tolerability.
- [10]
An estimated 15% of Americans experience migraines, with women disproportionately affected.
- [11]
Per the recommendations, clinicians should check how well treatments are working after eight to 12 weeks.
- [12]
Joanna Kempner, a Rutgers sociology professor who studies the politics of pain and was not involved in the recommendations, said a strong recommendation provides physicians with much-needed ammunition in their fights for prior authorization.
- [13]
Kempner said better outcomes depend on patients' ability to seek and afford health care.
- [14]
The recommendations are sorted based on qualifications, such as whether evidence of efficacy is a top concern versus tolerability or long-term safety, with separate recommendations for patients with a high body mass index, fibromyalgia, or hypertension, or who might be pregnant.
- [15]
The scientific review found the tricyclic antidepressant amitriptyline to be a viable migraine treatment option for some pregnant patients, but the American College of Obstetricians and Gynecologists advises against using tricyclic antidepressants during pregnancy due to the risk of major congenital abnormalities and other serious problems.
- [16]
Starling said migraine is a genetic neurologic disease, but the most common type is not based on a single mutation and instead involves multiple genetic variants that lead to vulnerability.
- [17]
CGRP is a protein involved in migraine; its levels rise during a migraine attack and fall when an attack has been well-treated or resolved.
- [18]
The American Headache Society has a position statement indicating that CGRP-targeted treatment options for migraine prevention should be considered first-line treatment options.
- [19]
Starling said treatment choice currently rests on patient preference about how the medication is delivered and on comorbidities, and that when patients ask which medication is best she often answers, "the one that you will take."
- [20]
Some preventive drugs come in tablet form, while others are injected under the skin or infused into a vein.
- [21]
The CGRP-targeting drugs were also recommended as a preventive option for patients who frequently rely on pain medication once their attacks begin.
- [22]
At least six FDA approvals for migraine prevention spread across the 14-year gap between guideline updates is an average of about one new approval every 28 months.
- [23]
Three sequential preventive drug trials assessed on the recommended eight-to-12-week schedule take 24 to 36 weeks, about six to nine months.
- [24]
CGRP-targeted drugs, like Aimovig and Ajovy, have reduced migraines in up to 70 percent of the people who take them.
- [25]
The group the guidelines say should be offered preventive treatment is roughly 8 million adults in the United States.
- [26]
Andrew Charles, director of the UCLA Goldberg Migraine Program and immediate past president of the headache society, who was not involved in creating the guidelines, said: "Frankly, I think it's going to scare away primary care doctors from using it because of how complicated it is."
Sources
2 independent publishers whose own reporting we read for this story.
- sciencenews.orgMigraine drugs are getting more precise. Choosing the right one is still tricky
1 article · August 31, 2026
- statnews.comNew guidelines on migraine prevention reflect increasing options for patients
1 article · August 31, 2026
Topics and entities
Topics
- CGRP-targeted therapeutics
- Prescribing in pregnancy and comorbidity
- Clinical Practice Guidelines
- Migraine prevention
- Payer coverage and prior authorization
Entities
- Atogepant (Qulipta)
- Calcitonin gene-related peptide
- AAN/AHS migraine prevention guideline (2026)
- Galcanezumab (Emgality)
- American Headache Society
- Food and Drug Administration
- Fremanezumab (Ajovy)
- Eptinezumab (Vyepti)
- Erenumab (Aimovig)
- American College of Obstetricians and Gynecologists
- Rimegepant (Nurtec)
- American Academy of Neurology